Related Research Articles
Venture capital (VC) is a form of private equity financing that is provided by venture capital firms or funds to startups, early-stage, and emerging companies that have been deemed to have high growth potential or which have demonstrated high growth. Venture capital firms or funds invest in these early-stage companies in exchange for equity, or an ownership stake. Venture capitalists take on the risk of financing risky start-ups in the hopes that some of the firms they support will become successful. Because startups face high uncertainty, VC investments have high rates of failure. The start-ups are usually based on an innovative technology or business model and they are usually from the high technology industries, such as information technology (IT), clean technology or biotechnology.
Garrett Gruener is an American venture capitalist, most known as the founder of Ask.com and a co-founder of Alta Partners. He was also a candidate for the 2003 California recall special election from the Democratic Party, finishing 28th in a field of 135 candidates with 2,562 votes.
William P. Egan is an American venture capitalist. He is the founder and general partner at Alta Communications, a venture capital firm, and Marion Equity Partners, a private equity firm, both based in Boston, Massachusetts. Egan also founded Alta's predecessor firm, Burr, Egan, Deleage & Co. (BEDCO) in 1979 and has identified and backed several of America's leading growth companies in the information technology, life sciences, and communications industries. Egan is also a limited partner, along with fellow BEDCO founder Craig Burr, at Nobska Partners, also in Boston.
Khosla Ventures is an American venture capital firm founded by Vinod Khosla, focused on early-stage companies in the Internet, computing, mobile, silicon technology, biotechnology, healthcare and clean technology sectors.
Kosan Biosciences, Inc., is a pharmaceutical company which deals with cancer therapeutics medications. The company is currently working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.
Burr, Egan, Deleage & Co. (BEDCO) was a venture capital firm which focused on investments in information technology, communications, and healthcare/biotechnology companies.
Alta Communications is an American private equity firm primarily working with media and the communication sector. Based in Boston it specializes in digital marketing, media and telecommunications.
Polaris Partners is an investment firm that has partnered with entrepreneurs in the fields of healthcare and technology. The firm has partnered with enterprises in various stages of development.
Craig L. Burr is an early venture capital investor, notable for his role in the founding of two venture capital firms, Burr, Egan, Deleage & Co. (BEDCO) in 1979 and Alta Communications in 1996.
Matrix Partners is a US-based private equity investment firm focusing on venture capital investments. The firm invests in seed and early-stage companies in the United States and India, particularly in the software, communications, semiconductors, data storage, Internet or wireless sectors.
Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.
Dr. Jean Deleage Ph.D. (1940–2011) was an early venture capital investor responsible for the founding or co-founding of three notable venture capital firms since 1971: Sofinnova, Burr, Egan, Deleage & Co. and Alta Partners.
Terry McGuire is a co-founder and general partner of Polaris Partners based in the Boston office. McGuire focuses on life sciences investments.
Lux Capital is a venture capital firm founded by Peter Hébert, Robert Paull, and Josh Wolfe in 2000. The firm, based in New York City with an office in Menlo Park, invests in emerging technologies in the physical and life sciences.
Spectrum Equity is an American growth equity firm that invests in businesses related to the information economy. The company operates out of offices in Boston, MA and San Francisco, CA. The company focuses on Software and Information Services; Internet and Digital Media; and Communications, Media and Entertainment, and typical equity investments range from $25 – $150 million.
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015, with $280 million in commitments.
Jonathan A. Flint is a venture capitalist and entrepreneur who co-founded the venture capital firms Polaris Partners and Polaris Founders Capital, as well as the companies Living Proof, and Icelandic Provisions.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, businessman, and investor.
Venture capital in Poland is a segment of the private equity market that finances early-stage high-risk companies based in Poland, with the potential for fast growth. As of March 2019, there is a total of 130 active VC firms in Poland, including local offices of international VC firms, and VC firms with mainly Polish management teams. Between 2009–2019, these entities have invested locally in over 750 companies, which gives an average of around 9 companies per portfolio. The Polish venture market accounts for 3% of the entire European ecosystem of VC investments, mainly in the digital space.
References
- ↑ "Carlsbad's Tyra Biosciences nets $50 million to combat drug resistance in cancer therapies". San Diego Union-Tribune. 2020-01-21. Retrieved 2020-04-23.
- Gupta, Udayan. Done Deals: Venture Capitalists Tell Their Stories, 2000
- Venture-Capital Firms Prepare for Next Generation of Partners
- Jean Deleage (Forbes Profile)
